Biasca, January 13, 2026. HAS Healthcare Announces Strategic Investment Plan to Strengthen Its Presence in Biasca

HAS Healthcare Advanced Synthesis SA Group, formed through the integration of HAS and Cerbios, has unveiled a five-year strategic investment plan exceeding CHF 100 million to strengthen its leadership in CDMO services and ADC (Antibody-Drug Conjugates) manufacturing. The investments will focus on expanding capacity and capabilities at the Biasca and Lugano sites, including new large-scale conjugation lines (up to 500 L), with the first line operational by May 2026 and a second by Q1 2028. The plan also includes hiring additional qualified professionals to support growth and enhance the group’s scientific and technological expertise.

Read the full press release here.